公开(公告)号：US20190153113A1

公开(公告)日：2019-05-23

申请号：US15778202

申请日：2016-11-22

Applicant: INNATE PHARMA ,  OREGA BIOTECH

Inventor： Jérémy BASTID ,  Laurent GAUTHIER ,  Carine PATUREL ,  Ivan PERROT ,  Alain ROUSSEL ,  Béatrice AMIGUES

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.

公开(公告)号：US20180369373A1

公开(公告)日：2018-12-27

申请号：US15747190

申请日：2016-07-04

Applicant: INNATE PHARMA

Inventor： NADIA ANCERIZ ,  CECILE BONNAFOUS ,  ARNAUD DUJARDIN ,  CARINE PATUREL

IPC: A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  G01N33/566 ,  G01N33/574

Abstract: The present invention relates to methods for detecting and monitoring NK cells in paraffin-embedded tissue samples. Also provided are antibodies, antibody fragments, and derivatives thereof that specifically bind to NKp46 present on the surface of NK cells in paraffin-embedded tissue samples.

公开(公告)号：US10071169B2

公开(公告)日：2018-09-11

申请号：US14898693

申请日：2014-06-20

Applicant: Innate Pharma

Inventor： Delphine Bregeon

IPC: A61K47/48 ,  A61K38/05 ,  C07K16/00 ,  C12P21/00

CPC classification number: A61K47/6811 ,  A61K38/05 ,  A61K47/6803 ,  C07K16/00 ,  C07K2317/14 ,  C12P21/005

Abstract: One embodiment relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

公开(公告)号：US20180216069A1

公开(公告)日：2018-08-02

申请号：US15876839

申请日：2018-01-22

Applicant: INNATE PHARMA

Inventor： Alessandro Moretta ,  Mariella Della Chiesa

IPC: C12N5/0783

Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

公开(公告)号：US10036010B2

公开(公告)日：2018-07-31

申请号：US14441157

申请日：2013-11-08

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Eliane Fischer ,  François Romagne ,  Patrick Dennler

IPC: C40B40/10 ,  C12N15/10 ,  B82Y5/00 ,  A61K47/68

CPC classification number: C12N15/1065 ,  A61K47/6889 ,  A61K47/6898 ,  B82Y5/00 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2318/00 ,  C07K2318/20 ,  C07K2319/41 ,  C07K2319/70 ,  C07K2319/90 ,  C12N15/1037 ,  C40B40/10

Abstract: The present application relates to methods for the functionalization of antibodies using transglutaminase, in particular antibodies lacking Fc regions. Also disclosed herein are peptide tags for transglutaminase, linking reagents, functionalized antibodies, multi-specific antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

公开(公告)号：US20170298132A1

公开(公告)日：2017-10-19

申请号：US15623572

申请日：2017-06-15

Applicant: INNATE PHARMA

Inventor： CECILE BONNAFOUS ,  HELENE SICARD ,  RENAUD BUFFET

IPC: C07K16/28 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/3023 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/732 ,  G01N33/57426 ,  G01N2333/705 ,  G01N2333/70503

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US09789182B2

公开(公告)日：2017-10-17

申请号：US14437029

申请日：2013-10-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  Innate Pharma

Inventor： Robert F. Graziano ,  Ashok K. Gupta ,  Su Young Kim ,  Jon Wigginton ,  Pascale Andre

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/565 ,  C07K2317/92

Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

公开(公告)号：US20170291947A1

公开(公告)日：2017-10-12

申请号：US15511778

申请日：2015-09-15

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

公开(公告)号：US20160369002A1

公开(公告)日：2016-12-22

申请号：US15190337

申请日：2016-06-23

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30 ,  A61K39/001102 ,  A61K39/001104

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Abstract translation: 在不存在靶细胞的情况下，提供结合并特异性地重定向NK细胞以裂解感兴趣的靶细胞的多特异性蛋白质而没有NK细胞的非特异性激活。 这些蛋白质可用于治疗疾病，特别是癌症或感染性疾病。

公开(公告)号：US09427478B2

公开(公告)日：2016-08-30

申请号：US14582040

申请日：2014-12-23

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Laurent Gauthier ,  François Romagne ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/48 ,  C07K16/00 ,  C07K16/30 ,  C07K19/00 ,  A61K31/5517

CPC classification number: A61K47/48569 ,  A61K31/5517 ,  A61K47/48384 ,  A61K47/48715 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/40

Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

Abstract translation: 本申请涉及免疫球蛋白的酶官能化方法，特别是与药物的方法。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法。